The focus of the venture, established in April 2018, is to develop microbial therapies for inflammatory bowel diseases.
Nikkei Biotech news release, July 4, 2018
The focus of the venture, established in April 2018, is to develop microbial therapies for inflammatory bowel diseases.
Nikkei Biotech news release, July 4, 2018